Join our daily newsletter At The Bell to receive exclusive market insights
- Prescient Therapeutics (PTX) has progressed its phase 1b study of PTX-200 and cytarabine in acute myeloid leukemia (AML) patients to the next dose level
- The first cohort at 25 mg/m2 PTX-200 has been completed and will progress to the next dose level of 35 mg/m2
- This modification was made to try and minimise the potential for overlapping drug interactions that could potentially lead to side effects
- As previously reported, three out of 15 patients experienced complete responses in the highly encouraging study
- Company shares are trading a slight 1.79 per cent and are trading for 5.7 cents
Prescient Therapeutics’ (PTX) Phase 1b study of PTX-200 and cytarabine in acute myeloid leukemia (AML) patients successfully completed the first cohort at 25 mg/m2 PTX-200.
No dose limiting toxicities were observed and therapy was better tolerated than under the previous dosing schedule.
The study has now progressed to the next dose level of 35 mg/m2 PTX-200. This cohort is actively screening.
This modification was made to try and minimise the potential for overlapping drug interactions that could potentially lead to side effects.
The modification includes maintaining the day one dose of PTX-200 and removing days eight and 15, whilst delaying the start of the cytarabine five-day continuous infusion to days three to seven of a 21-day cycle.
As previously reported, three out of 15 patients experienced complete responses (meaning little to no evidence of the disease) in the study in relapsed or refractory AML patients, which is a difficult-to-treat cancer population.
“We look forward to escalating the dose in this next cohort as we seek to expand on the encouraging responses previously observed in this study, in a patient population that is difficult to treat and has limited treatment options,” Chief Medical Officer Dr Terrence Chew said.
PTX-200is a novel inhibitor drug that inhibits an important tumour survival pathway known as Akt. Akt plays a key role in the development of many cancers, including breast and ovarian cancer, as well as leukemia.
Company shares are trading a slight 1.79 per cent and are trading for 5.7 cents each at 1:49 pm AEST.
